Výsledky vyhledávání

Akademický článek

Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study

Autor: Altafini R, Scherzer ML, Hubatsch DA, Frezzotti P

Publikováno v: Clinical Ophthalmology, Vol 2015, Iss default, Pp 2263-2270 (2015)

Romeo Altafini,1 Maria-Luise Scherzer,2 Douglas A Hubatsch,3 Paolo Frezzotti4 1Glaucoma Segment Unit, “San Bortolo” Hospital, Vicenza, Italy; 2Private Practice, Regenstauf, Germany; 3Alcon Laboratories, Inc., Fort Worth, TX, USA; 4Ophthalmic Unit

Externí odkaz: https://doaj.org/article/b75fbe31e7f5461badc301a03f8b8655

Zobrazit plný text záznamu

Akademický článek

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy

Autor: Schnober D, Hubatsch DA, Scherzer ML

Publikováno v: Clinical Ophthalmology, Vol 2015, Iss default, Pp 825-832 (2015)

Dietmar Schnober,1 Douglas A Hubatsch,2 Maria-Luise Scherzer3 1Private Ophthalmology Practice, Werdohl, Germany; 2Alcon Laboratories, Inc., Fort Worth, TX, USA; 3Private Ophthalmology Practice, Regenstauf, Germany Purpose: To determine the efficacy a

Externí odkaz: https://doaj.org/article/9808f3ef76cb44d89a62782936cf2bc7

Zobrazit plný text záznamu

Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension

Publikováno v: Eye. 24:1234-1242

Aims To compare intraocular pressure (IOP) reductions with fixed-combination (FC) latanoprost/timolol once daily in the evening vsFC dorzolamide/timolol twice daily. Methods This evaluator-masked, multicentre, controlled clinical trial randomized sub

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74f756ba0527ca0672a8d354303da44d
https://doi.org/10.1038/eye.2009.307

Zobrazit plný text záznamu

Akademický článek

Travoprost 0.004%/timolol 0.5% fixed combination in patients transitioning from fixed or unfixed bimatoprost 0.03%/timolol 0.5%.

Autor: Scherzer ML; Marktplatz, Regenstauf, Germany. ErnstES139Scherzer_ES@web.de, Liehneova I, Negrete FJ, Schnober D

Publikováno v: Advances in therapy [Adv Ther] 2011 Aug; Vol. 28 (8), pp. 661-70. Date of Electronic Publication: 2011 Jul 15.

Zobrazit plný text záznamu

Akademický článek

Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension.

Autor: Schnober D; Private Practices, Werdohl, Germany. dr.schnober@t-online.de, Hofmann G, Maier H, Scherzer ML, Ogundele AB, Jasek MC

Publikováno v: Clinical ophthalmology (Auckland, N.Z.) [Clin Ophthalmol] 2010 Dec 08; Vol. 4, pp. 1459-63. Date of Electronic Publication: 2010 Dec 08.

Zobrazit plný text záznamu

Akademický článek

Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy.

Autor: Pfeiffer N; Johannes Gutenberg-Universität Mainz, Mainz, Germany., Scherzer ML, Maier H, Schoelzel S, Jasek MC, Stewart JA, Stewart WC

Publikováno v: Clinical ophthalmology (Auckland, N.Z.) [Clin Ophthalmol] 2010 May 14; Vol. 4, pp. 459-66. Date of Electronic Publication: 2010 May 14.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání